Skip to main content
SOLIGENIX, INC. logo

SOLIGENIX, INC. — Investor Relations & Filings

Ticker · SNGX ISIN · US8342233074 LEI · 549300MN2EF9LQHLT817 US Manufacturing
Open in API
Filings indexed 1,025 across all filing types
Latest filing 2026-05-28 Regulatory Filings
Country US United States of America
Listing US SNGX

About SOLIGENIX, INC.

https://www.soligenix.com/

Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases with unmet medical needs. The company operates through two main segments: Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics pipeline develops treatments for orphan diseases. The Public Health Solutions pipeline, funded by government grants and contracts, focuses on developing vaccines and therapeutics for infectious diseases and biodefense applications, including a program to prevent ricin poisoning.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings
2026-05-28 English
424B5
Capital/Financing Update Classification · 85% confidence The document is a Form 424B5 Prospectus Supplement filed pursuant to Rule 424(b)(5) amending and supplementing an existing S-3 registration statement for an at-market common stock issuance. It announces updates to the maximum dollar amount of shares available under the Sales Agreement, which is a financing activity. This type of document is a capital/financing update rather than an annual or interim report, director change, or dividend notice.
2026-05-28 English
424B3
Interim / Quarterly Report Classification · 95% confidence The document is a Prospectus Supplement under Rule 424(b)(3) that contains the full text of a Form 10-Q for the quarter ended March 31, 2026, including detailed financial statements, notes, and Management’s Discussion and Analysis. This is an interim/quarterly report with substantive financial disclosures, matching the definition of an Interim/Quarterly Report (Code: IR). Q1 2026
2026-05-08 English
424B3 - SOLIGENIX, INC. (0000812796) (Filer)
Interim / Quarterly Report Classification · 91% confidence The document is a SEC Form 424(b)(3) prospectus supplement that “contains the Quarterly Report on Form 10-Q for the quarter ended March 31, 2026” and then reproduces the full interim financial statements and MD&A. It is the complete quarterly/interim report (Form 10-Q) rather than a mere announcement or certification. Therefore it should be classified as an Interim/Quarterly Report (IR). Q1 2026
2026-05-08 English
424B3 - SOLIGENIX, INC. (0000812796) (Filer)
Interim / Quarterly Report Classification · 97% confidence The document is a Form 10-Q (Quarterly Report) for the period ended March 31, 2026, including full financial statements, MD&A, risk factors, legal proceedings, exhibits, etc. It is not merely an announcement or certification; it is the interim financial report itself. Therefore it falls under Interim/Quarterly Report (IR). Q1 2026
2026-05-08 English
424B3
Capital/Financing Update Classification · 80% confidence The document is a Form 424B3 “Prospectus Supplement No. 1” filed pursuant to Rule 424(b)(3) in connection with the public offering of 5,330,560 shares of common stock underlying previously issued warrants. Although it contains a Form 10-Q inside, the filing itself is a securities offering document, i.e., an equity financing update. Under the provided taxonomy, this fits “Capital/Financing Update (CAP)” rather than a standalone quarterly report or generic regulatory filing.
2026-05-08 English

Browse filings by year

20 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.